P/E ratio for Tandem Diabetes Care (TNDM)
P/E ratio as of April 2024 (TTM): -10.9
According to Tandem Diabetes Care 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.9319. At the end of 2022 the company had a P/E ratio of -30.6.
P/E ratio history for Tandem Diabetes Care from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -30.6 | -104.88% |
| 2021 | 627 | -480.18% |
| 2020 | -165 | 21.77% |
| 2019 | -135 | 1166.64% |
| 2018 | -10.7 | 7214.82% |
| 2017 | -0.1462 | -81.41% |
| 2016 | -0.7867 | -83.15% |
| 2015 | -4.67 | 25.7% |
| 2014 | -3.71 | -45.95% |
| 2013 | -6.87 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.4 | -194.90% | 🇺🇸 USA |
 Medtronic MDT | 29.3 | -368.17% | 🇮🇪 Ireland |
 ICU Medical
ICUI | -47.0 | 330.30% | 🇺🇸 USA |
 DexCom DXCM | 127 | -1,261.83% | 🇺🇸 USA |
 Insulet PODD | 96.6 | -983.70% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.